Toward molecular targeting with specific intravenous immunoglobulin preparation View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-12

AUTHORS

Miri Blank, Israel Nur, Orgad Toub, Anabel Maor, Yehuda Shoenfeld

ABSTRACT

Intravenous immunoglobulin (IVIg) is used successfully for therapy of inflammatory and autoimmune diseases, especially in cases of conventional therapy resistance. Within the broad spectrum of immunoregulatory activities of IVIg in vitro and in vivo, the anti-idiotypic activity neutralizing the related idiotypes is one of the main mechanisms. Furthermore, IVIg addresses integrins associated with inflammation and immune response thrombosis, such as the RGD (Arg-Gly-Asp) motif, expressed on a large number of cell surface and matrix proteins. In addition, during the last years, anti-Fas activity of IVIg was reported. We fractionated IVIg specific preparation (sIVIg) based on the multispecificities of the IVIg compound. We have generated an IVIg fraction that will show specific activity for lupus idiotypes in vitro. In NZBxW.F1 mice, results showed 200 times more beneficial effect. Using a peptide phage display library technology, we have identified a panel of lupus-related synthetic idiotypes that are mimetics of the idiotypes presented in patients with systemic lupus erythematosus. A column composed of these synthetic lupus-related idiotypes was used to prepare a large amount lupus-specific IVIg. Using the same approach, we prepared anti-anti-beta-2-glycoprotein-I (beta2GPI) specific IVIg for antiphospholipid syndrome (APS). This APS-specific IVIg reduced the fetal loss induced by anti-beta2GPI antibodies by improving the implantation process in a mouse model. Others prepared specific preparations of IVIg to RGD or for Fas. The molecular targeting with specific IVIg may be used for therapeutical purposes, using a smaller amount of IVIg, and targeting more specifically autoimmune diseases, thrombosis, or inflammatory condition. More... »

PAGES

213-217

Identifiers

URI

http://scigraph.springernature.com/pub.10.1385/criai:29:3:213

DOI

http://dx.doi.org/10.1385/criai:29:3:213

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010355944

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16391396


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Anti-Idiotypic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiphospholipid Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fas Ligand Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoglobulins, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lupus Erythematosus, Systemic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptide Library", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tel Aviv University", 
          "id": "https://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Department of Medicine \u2018B\u2019 and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel", 
            "The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blank", 
        "givenName": "Miri", 
        "id": "sg:person.01336511465.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336511465.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johnson & Johnson (Israel)", 
          "id": "https://www.grid.ac/institutes/grid.474389.5", 
          "name": [
            "OMRIX Biopharmaceuticals Inc., Nes-Ziona, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nur", 
        "givenName": "Israel", 
        "id": "sg:person.01127104672.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127104672.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johnson & Johnson (Israel)", 
          "id": "https://www.grid.ac/institutes/grid.474389.5", 
          "name": [
            "OMRIX Biopharmaceuticals Inc., Nes-Ziona, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toub", 
        "givenName": "Orgad", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tel Aviv University", 
          "id": "https://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Department of Medicine \u2018B\u2019 and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel", 
            "The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maor", 
        "givenName": "Anabel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tel Aviv University", 
          "id": "https://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Department of Medicine \u2018B\u2019 and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel", 
            "Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel Aviv University, Tel Aviv, Israel", 
            "The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shoenfeld", 
        "givenName": "Yehuda", 
        "id": "sg:person.01010756664.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010756664.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1177/096120339300200607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000518523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/096120339300200607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000518523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/096120339300200607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000518523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2249.1994.tb06573.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004926118"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)90701-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006860423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)90701-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006860423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0167-5699(91)90122-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008185143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.1780280907", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018859490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)92904-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019000762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(84)92904-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019000762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-003-0081-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025993578", 
          "https://doi.org/10.1007/s10072-003-0081-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2249.1999.00930.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026808971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-510x(96)00053-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030559618"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/clin.1993.1064", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032530670"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199201093260206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033530121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra993360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034454051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/intimm/dxf099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036221794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2249.1994.tb05509.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037945368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0896-8411(92)90153-h", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040503413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2249.1991.tb05631.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040732542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.semarthrit.2004.07.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046365233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1521-4141(200212)32:12<3414::aid-immu3414>3.0.co;2-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046563926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/jaut.1994.1039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047166323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00690290", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049917070", 
          "https://doi.org/10.1007/bf00690290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00918187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050715693", 
          "https://doi.org/10.1007/bf00918187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/clin.1993.1155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052365476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.2821619", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062563620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.21.4.875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071514793"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074463109", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079079854", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083023934", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083309228", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083324957", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-12", 
    "datePublishedReg": "2005-12-01", 
    "description": "Intravenous immunoglobulin (IVIg) is used successfully for therapy of inflammatory and autoimmune diseases, especially in cases of conventional therapy resistance. Within the broad spectrum of immunoregulatory activities of IVIg in vitro and in vivo, the anti-idiotypic activity neutralizing the related idiotypes is one of the main mechanisms. Furthermore, IVIg addresses integrins associated with inflammation and immune response thrombosis, such as the RGD (Arg-Gly-Asp) motif, expressed on a large number of cell surface and matrix proteins. In addition, during the last years, anti-Fas activity of IVIg was reported. We fractionated IVIg specific preparation (sIVIg) based on the multispecificities of the IVIg compound. We have generated an IVIg fraction that will show specific activity for lupus idiotypes in vitro. In NZBxW.F1 mice, results showed 200 times more beneficial effect. Using a peptide phage display library technology, we have identified a panel of lupus-related synthetic idiotypes that are mimetics of the idiotypes presented in patients with systemic lupus erythematosus. A column composed of these synthetic lupus-related idiotypes was used to prepare a large amount lupus-specific IVIg. Using the same approach, we prepared anti-anti-beta-2-glycoprotein-I (beta2GPI) specific IVIg for antiphospholipid syndrome (APS). This APS-specific IVIg reduced the fetal loss induced by anti-beta2GPI antibodies by improving the implantation process in a mouse model. Others prepared specific preparations of IVIg to RGD or for Fas. The molecular targeting with specific IVIg may be used for therapeutical purposes, using a smaller amount of IVIg, and targeting more specifically autoimmune diseases, thrombosis, or inflammatory condition.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1385/criai:29:3:213", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094155", 
        "issn": [
          "1080-0549", 
          "1559-0267"
        ], 
        "name": "Clinical Reviews in Allergy & Immunology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "29"
      }
    ], 
    "name": "Toward molecular targeting with specific intravenous immunoglobulin preparation", 
    "pagination": "213-217", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3156026001fdbe6de8e4f9b4ff529e2bf8208307a1f11c611940d0f019f6f3d3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16391396"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9504368"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1385/criai:29:3:213"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010355944"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1385/criai:29:3:213", 
      "https://app.dimensions.ai/details/publication/pub.1010355944"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000536.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1385%2FCRIAI%3A29%3A3%3A213"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1385/criai:29:3:213'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1385/criai:29:3:213'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1385/criai:29:3:213'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1385/criai:29:3:213'


 

This table displays all metadata directly associated to this object as RDF triples.

233 TRIPLES      21 PREDICATES      70 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1385/criai:29:3:213 schema:about N2013b6546cc14c8badc2bf8c299f3337
2 N23893a5d3a5b485fb0808fca8e334933
3 N24f9e02e94a94d3ca91e44bd90665d97
4 N312ac7de4f2a4fd7b89db834be1e1ffa
5 N3ef36e13282b4ccf837fba3e7eb89853
6 N4b0f79a5a6824447b86a196c9c42ce47
7 N7064943dc0104a93808e81253712260a
8 N7d874f3ced524c39a78c9827a054c935
9 N7f9fd1d6b6b34d5e9752e98d22d439f1
10 N8008fb00b73b4ca884edc41644fea301
11 Ne0ad58e171394528a7141b13911bfdfc
12 Ne27fc3a79be34bc0b6d8c8cf4fbdb65b
13 anzsrc-for:11
14 anzsrc-for:1107
15 schema:author N2e212be2b3c141c7907ddbaa35eb7f2a
16 schema:citation sg:pub.10.1007/bf00690290
17 sg:pub.10.1007/bf00918187
18 sg:pub.10.1007/s10072-003-0081-7
19 https://app.dimensions.ai/details/publication/pub.1074463109
20 https://app.dimensions.ai/details/publication/pub.1079079854
21 https://app.dimensions.ai/details/publication/pub.1083023934
22 https://app.dimensions.ai/details/publication/pub.1083309228
23 https://app.dimensions.ai/details/publication/pub.1083324957
24 https://doi.org/10.1002/1521-4141(200212)32:12<3414::aid-immu3414>3.0.co;2-f
25 https://doi.org/10.1002/art.1780280907
26 https://doi.org/10.1006/clin.1993.1064
27 https://doi.org/10.1006/clin.1993.1155
28 https://doi.org/10.1006/jaut.1994.1039
29 https://doi.org/10.1016/0022-510x(96)00053-6
30 https://doi.org/10.1016/0167-5699(91)90122-a
31 https://doi.org/10.1016/0896-8411(92)90153-h
32 https://doi.org/10.1016/j.semarthrit.2004.07.002
33 https://doi.org/10.1016/s0140-6736(84)90701-3
34 https://doi.org/10.1016/s0140-6736(84)92904-0
35 https://doi.org/10.1046/j.1365-2249.1999.00930.x
36 https://doi.org/10.1056/nejm199201093260206
37 https://doi.org/10.1056/nejmra993360
38 https://doi.org/10.1093/intimm/dxf099
39 https://doi.org/10.1111/j.1365-2249.1991.tb05631.x
40 https://doi.org/10.1111/j.1365-2249.1994.tb05509.x
41 https://doi.org/10.1111/j.1365-2249.1994.tb06573.x
42 https://doi.org/10.1126/science.2821619
43 https://doi.org/10.1177/096120339300200607
44 https://doi.org/10.3892/ijo.21.4.875
45 schema:datePublished 2005-12
46 schema:datePublishedReg 2005-12-01
47 schema:description Intravenous immunoglobulin (IVIg) is used successfully for therapy of inflammatory and autoimmune diseases, especially in cases of conventional therapy resistance. Within the broad spectrum of immunoregulatory activities of IVIg in vitro and in vivo, the anti-idiotypic activity neutralizing the related idiotypes is one of the main mechanisms. Furthermore, IVIg addresses integrins associated with inflammation and immune response thrombosis, such as the RGD (Arg-Gly-Asp) motif, expressed on a large number of cell surface and matrix proteins. In addition, during the last years, anti-Fas activity of IVIg was reported. We fractionated IVIg specific preparation (sIVIg) based on the multispecificities of the IVIg compound. We have generated an IVIg fraction that will show specific activity for lupus idiotypes in vitro. In NZBxW.F1 mice, results showed 200 times more beneficial effect. Using a peptide phage display library technology, we have identified a panel of lupus-related synthetic idiotypes that are mimetics of the idiotypes presented in patients with systemic lupus erythematosus. A column composed of these synthetic lupus-related idiotypes was used to prepare a large amount lupus-specific IVIg. Using the same approach, we prepared anti-anti-beta-2-glycoprotein-I (beta2GPI) specific IVIg for antiphospholipid syndrome (APS). This APS-specific IVIg reduced the fetal loss induced by anti-beta2GPI antibodies by improving the implantation process in a mouse model. Others prepared specific preparations of IVIg to RGD or for Fas. The molecular targeting with specific IVIg may be used for therapeutical purposes, using a smaller amount of IVIg, and targeting more specifically autoimmune diseases, thrombosis, or inflammatory condition.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree false
51 schema:isPartOf N5b0cb8568d5141e1bd84dc9fc6c19ebe
52 Nd56f918cf3e64cd38d1e92ad9a7f8c51
53 sg:journal.1094155
54 schema:name Toward molecular targeting with specific intravenous immunoglobulin preparation
55 schema:pagination 213-217
56 schema:productId N082cc15b739e4609ae44d84d2e873ec3
57 N17e226f3bc1045aca99e614675d77022
58 N2347dce9c5d04ef0a00b7b98d74b5c97
59 N6a67e7e880e44f31b089f3f0d7ecc794
60 N8571ee37417447cf8d7f525f8e8f0def
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010355944
62 https://doi.org/10.1385/criai:29:3:213
63 schema:sdDatePublished 2019-04-10T20:51
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N1d05fa23470f48928115c90e5cb0a5a3
66 schema:url http://link.springer.com/10.1385%2FCRIAI%3A29%3A3%3A213
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N010dcb6f69a546a491c27da1f5a3dd16 schema:affiliation https://www.grid.ac/institutes/grid.474389.5
71 schema:familyName Toub
72 schema:givenName Orgad
73 rdf:type schema:Person
74 N082cc15b739e4609ae44d84d2e873ec3 schema:name readcube_id
75 schema:value 3156026001fdbe6de8e4f9b4ff529e2bf8208307a1f11c611940d0f019f6f3d3
76 rdf:type schema:PropertyValue
77 N08ce347a8dc64305b64fb115ca683f9f rdf:first sg:person.01127104672.57
78 rdf:rest N1fd5cb271bc748338e726e618d379412
79 N17e226f3bc1045aca99e614675d77022 schema:name nlm_unique_id
80 schema:value 9504368
81 rdf:type schema:PropertyValue
82 N1d05fa23470f48928115c90e5cb0a5a3 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 N1fd5cb271bc748338e726e618d379412 rdf:first N010dcb6f69a546a491c27da1f5a3dd16
85 rdf:rest N72c06da31129414ea3eddad0e8845d79
86 N2013b6546cc14c8badc2bf8c299f3337 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 N2347dce9c5d04ef0a00b7b98d74b5c97 schema:name dimensions_id
90 schema:value pub.1010355944
91 rdf:type schema:PropertyValue
92 N23893a5d3a5b485fb0808fca8e334933 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Fas Ligand Protein
94 rdf:type schema:DefinedTerm
95 N24f9e02e94a94d3ca91e44bd90665d97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Membrane Glycoproteins
97 rdf:type schema:DefinedTerm
98 N2e212be2b3c141c7907ddbaa35eb7f2a rdf:first sg:person.01336511465.47
99 rdf:rest N08ce347a8dc64305b64fb115ca683f9f
100 N312ac7de4f2a4fd7b89db834be1e1ffa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Animals
102 rdf:type schema:DefinedTerm
103 N3ef36e13282b4ccf837fba3e7eb89853 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Lupus Erythematosus, Systemic
105 rdf:type schema:DefinedTerm
106 N4b0f79a5a6824447b86a196c9c42ce47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Peptide Library
108 rdf:type schema:DefinedTerm
109 N5b0cb8568d5141e1bd84dc9fc6c19ebe schema:issueNumber 3
110 rdf:type schema:PublicationIssue
111 N6a67e7e880e44f31b089f3f0d7ecc794 schema:name pubmed_id
112 schema:value 16391396
113 rdf:type schema:PropertyValue
114 N7064943dc0104a93808e81253712260a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Mice
116 rdf:type schema:DefinedTerm
117 N72c06da31129414ea3eddad0e8845d79 rdf:first Nde557bc99de94f6da790623bd6680c9a
118 rdf:rest N86b7ac73d6e74bde917565130f4253ec
119 N7d874f3ced524c39a78c9827a054c935 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Immunoglobulins, Intravenous
121 rdf:type schema:DefinedTerm
122 N7f9fd1d6b6b34d5e9752e98d22d439f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Tumor Necrosis Factors
124 rdf:type schema:DefinedTerm
125 N8008fb00b73b4ca884edc41644fea301 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Oligopeptides
127 rdf:type schema:DefinedTerm
128 N8571ee37417447cf8d7f525f8e8f0def schema:name doi
129 schema:value 10.1385/criai:29:3:213
130 rdf:type schema:PropertyValue
131 N86b7ac73d6e74bde917565130f4253ec rdf:first sg:person.01010756664.44
132 rdf:rest rdf:nil
133 Nd56f918cf3e64cd38d1e92ad9a7f8c51 schema:volumeNumber 29
134 rdf:type schema:PublicationVolume
135 Nde557bc99de94f6da790623bd6680c9a schema:affiliation https://www.grid.ac/institutes/grid.12136.37
136 schema:familyName Maor
137 schema:givenName Anabel
138 rdf:type schema:Person
139 Ne0ad58e171394528a7141b13911bfdfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Antiphospholipid Syndrome
141 rdf:type schema:DefinedTerm
142 Ne27fc3a79be34bc0b6d8c8cf4fbdb65b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Antibodies, Anti-Idiotypic
144 rdf:type schema:DefinedTerm
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
149 schema:name Immunology
150 rdf:type schema:DefinedTerm
151 sg:journal.1094155 schema:issn 1080-0549
152 1559-0267
153 schema:name Clinical Reviews in Allergy & Immunology
154 rdf:type schema:Periodical
155 sg:person.01010756664.44 schema:affiliation https://www.grid.ac/institutes/grid.12136.37
156 schema:familyName Shoenfeld
157 schema:givenName Yehuda
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010756664.44
159 rdf:type schema:Person
160 sg:person.01127104672.57 schema:affiliation https://www.grid.ac/institutes/grid.474389.5
161 schema:familyName Nur
162 schema:givenName Israel
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127104672.57
164 rdf:type schema:Person
165 sg:person.01336511465.47 schema:affiliation https://www.grid.ac/institutes/grid.12136.37
166 schema:familyName Blank
167 schema:givenName Miri
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336511465.47
169 rdf:type schema:Person
170 sg:pub.10.1007/bf00690290 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049917070
171 https://doi.org/10.1007/bf00690290
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/bf00918187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050715693
174 https://doi.org/10.1007/bf00918187
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s10072-003-0081-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025993578
177 https://doi.org/10.1007/s10072-003-0081-7
178 rdf:type schema:CreativeWork
179 https://app.dimensions.ai/details/publication/pub.1074463109 schema:CreativeWork
180 https://app.dimensions.ai/details/publication/pub.1079079854 schema:CreativeWork
181 https://app.dimensions.ai/details/publication/pub.1083023934 schema:CreativeWork
182 https://app.dimensions.ai/details/publication/pub.1083309228 schema:CreativeWork
183 https://app.dimensions.ai/details/publication/pub.1083324957 schema:CreativeWork
184 https://doi.org/10.1002/1521-4141(200212)32:12<3414::aid-immu3414>3.0.co;2-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1046563926
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1002/art.1780280907 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018859490
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1006/clin.1993.1064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032530670
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1006/clin.1993.1155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052365476
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1006/jaut.1994.1039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047166323
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1016/0022-510x(96)00053-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030559618
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1016/0167-5699(91)90122-a schema:sameAs https://app.dimensions.ai/details/publication/pub.1008185143
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/0896-8411(92)90153-h schema:sameAs https://app.dimensions.ai/details/publication/pub.1040503413
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.semarthrit.2004.07.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046365233
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/s0140-6736(84)90701-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006860423
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0140-6736(84)92904-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019000762
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1046/j.1365-2249.1999.00930.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026808971
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1056/nejm199201093260206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033530121
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1056/nejmra993360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034454051
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1093/intimm/dxf099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036221794
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1111/j.1365-2249.1991.tb05631.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040732542
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1111/j.1365-2249.1994.tb05509.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037945368
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1111/j.1365-2249.1994.tb06573.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004926118
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1126/science.2821619 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062563620
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1177/096120339300200607 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000518523
223 rdf:type schema:CreativeWork
224 https://doi.org/10.3892/ijo.21.4.875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071514793
225 rdf:type schema:CreativeWork
226 https://www.grid.ac/institutes/grid.12136.37 schema:alternateName Tel Aviv University
227 schema:name Department of Medicine ‘B’ and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel
228 Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Tel Aviv University, Tel Aviv, Israel
229 The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
230 rdf:type schema:Organization
231 https://www.grid.ac/institutes/grid.474389.5 schema:alternateName Johnson & Johnson (Israel)
232 schema:name OMRIX Biopharmaceuticals Inc., Nes-Ziona, Israel
233 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...